R&D channel feed – Endpoints News

R&D channel feed

Charles River to close ‘15 smaller sites’ as demand for early research declines

6 months ago

Nkarta drops another cancer program as it leans into autoimmune disease

6 months ago

Athira gives up on lead Alzheimer’s drug, switches tack to ALS

6 months ago

Genmab chops early cancer prospects to prioritize Phase 3 projects

6 months ago

Aurinia cuts nearly half of its workforce in second round of layoffs this year

6 months ago

Denali teases early data for enzyme replacement therapy in rare disease

6 months ago

Gilead beats Covid drug sales forecasts, takes $1.75B hit on Trodelvy study fail

6 months ago

Arcus backs TIGIT combo by offering glimpse at positive data from axed trial

6 months ago

Sarepta discontinues work on next-gen exon-skipping drug for Duchenne

6 months ago

At this year's ObesityWeek, GLP-1s aren’t the only talk of the town

6 months ago

Novo unveils new cardiometabolic data as it reports solid third-quarter profits

6 months ago

‘We’re good’ on weight loss: Biopharmas turn to muscle with new obesity drugs

6 months ago

One biotech is looking to lessen antipsychotic-induced weight gain, despite new entrants

6 months ago

Novo Nordisk takes Forma’s sickle cell treatment into Phase 3

6 months ago

Zealand’s ‘aspirational’ mission for its amylin drug to be first-line in obesity

6 months ago

J&J's Darzalex hits primary endpoint in Phase 3 early-stage multiple myeloma trial

6 months ago

Gilead and Arcellx spotlight safety of multiple myeloma cell therapy, dose first patient in Phase 3

6 months ago

Sanofi reveals positive data for BTK inhibitor from $3.7B Principia takeover

6 months ago

Beam discloses first clinical data on base-edited sickle cell therapy, one patient death

6 months ago

Sana narrows focus again to zero in on diabetes and autoimmune disease

6 months ago

Viking CEO on ‘shocking’ market reaction to oral obesity data, preparing for Phase 3

6 months ago

BioNTech says VEGF bispecific’s PD-L1 target, combo plans will be its edge

6 months ago

'We play to win': AstraZeneca details first results for oral GLP-1 and broader obesity ambitions

6 months ago

Is there room for MASH drugs in a GLP-1 world?

6 months ago

First page Previous page 17 18 192021 22 23 Next page Last page